The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Hengrui Therapeutics; Lilly; Merck; Pfizer
Speakers' Bureau - Genentech
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Masatoshi Kudo
Honoraria - AstraZeneca; Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai
Research Funding - Abbvie (Inst); Chugai/Roche (Inst); EA Pharma (Inst); Eisai (Inst); GE Healthcare (Inst); Gilead Sciences (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Tim Meyer
Consulting or Advisory Role - Bayer; Beigene; BTG; Eisai; Ipsen; MSD; Roche
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Frederic Boisserie
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Songzi Li
No Relationships to Disclose
 
Yaxi Chen
Employment - BeiGene
 
Gisoo Barnes
No Relationships to Disclose
 
Ramil Abdrashitov
Employment - AstraZeneca (I); BeiGene
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I); BeiGene; Takeda
 
Andrew X. Zhu
Employment - I-Mab
Leadership - I-Mab
Stock and Other Ownership Interests - I-Mab
Consulting or Advisory Role - Bayer; Eisai; Exelixis; Lilly; Merck; Roche/Genentech; Sanofi
 
Arndt Vogel
Honoraria - Advanced Accelerator Applications/Imaging Equipment Ltd; Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Pharma GmbH; Boston Scientific; Bristol-Myers Squibb; Daichi-Sankyo; Eisai; GlaxoSmithKline; Incyte; Ipsen; Janssen; Lilly; MSD; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Sirtex Medical; Taiho Oncology; TERUMO
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Boehringer Pharma GmbH; BTG; Daichi-Sankyo; EISAI; Incyte; IPSEN; Lilly; Novartis; Pierre Fabre; Roche; Sirtex Medical; Taiho Oncology; Taiho Oncology; Terumo
Research Funding - Novartis
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Lilly; MSD; Roche